Evidence supporting the use of: Immunoglobulins
For the health condition: Influenza

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Immunoglobulins (also called antibodies) have been investigated and used as a therapeutic option for influenza, especially in severe cases or when other treatments are unavailable or ineffective. The use of convalescent plasma or hyperimmune globulin, which contains high titers of influenza-specific antibodies, has a historical precedent dating back to the 1918 influenza pandemic, where some observational studies suggested reduced mortality in recipients. More recently, several clinical studies and meta-analyses have assessed the efficacy of immunoglobulin therapy (either standard intravenous immunoglobulin [IVIG] or specific hyperimmune globulin) in treating severe influenza, particularly in hospitalized or immunocompromised patients.

The evidence is mixed. Some small randomized controlled trials and observational studies have suggested a possible reduction in viral load or improvement in clinical outcomes, but others have failed to show significant benefit. The 2018 Infectious Diseases Society of America (IDSA) guidelines acknowledge that data are insufficient to recommend routine use of immunoglobulin products for influenza, but they may be considered in certain severe or refractory cases. The overall quality of evidence is moderate (hence a rating of 3), with ongoing research needed to clarify which patients may benefit most. Immunoglobulins are not standard therapy for uncomplicated influenza, but their use in severe cases is supported by a moderate level of scientific evidence, particularly in the context of limited antiviral options.

More about Immunoglobulins
More about Influenza

Products containing Immunoglobulins

We currently have no products on Vitabase that contain this ingredient.